High-dose methotrexate is not associated with reduction in CNS relapse in patients with aggressive B-cell lymphoma: An international retrospective study of 2300 high-risk patients Meeting Abstract


Authors: Lewis, K. L.; Jakobsen, L. H.; Villa, D.; Bobillo, S.; Smedby, K. E.; Savage, K. J.; Eyre, T. A.; Cwynarski, K.; Caporn, P. L.; Van Zyl, J.; Klanova, M.; Trněný, M.; Puckrin, R.; Stewart, D. A.; Bishton, M. J.; Fox, C. P.; Tun, A. M.; Thanarajasingam, G.; Djebbari, F.; Joffe, E.; Eloranta, S.; Harrysson, S.; Sehn, L. H.; Maliske, S. M.; Poonsombudlert, K.; Guo, X.; Hapgood, G.; Manos, K.; Hawkes, E.; Khwaja, J.; Minson, A.; Dickinson, M.; Øvlisen, A. K.; Gregory, G. P.; Gilbertson, M.; Streit, I. T.; Scott, H. W.; Ku, M.; de Mel, S.; Yong, K. Y.; Xin, L.; Mokoonlall, M.; Talaulikar, D.; McVilly, N. L.; Johnston, A.; Brunner, M. J.; Pophali, P. A.; Maurer, M. J.; El-Galaly, T. C.; Cheah, C. Y.
Abstract Title: High-dose methotrexate is not associated with reduction in CNS relapse in patients with aggressive B-cell lymphoma: An international retrospective study of 2300 high-risk patients
Meeting Title: 63rd Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 138
Issue: Suppl. 1
Meeting Dates: 2021 Dec 11-14
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2021-11-23
Language: English
ACCESSION: WOS:000736398800179
DOI: 10.1182/blood-2021-146737
PROVIDER: wos
Notes: Meeting Abstract: 181 -- Hybrid meeting, also took place online -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Erel Joffe
    82 Joffe
Related MSK Work